Results from a University of Alabama at Birmingham study for a new HIV drug were recognized at the International AIDS Conference in Thailand that ended Friday.
UAB participated in the trials that brought the drug, Fuzeon (enfuvirtide), to market earlier this year. Fuzeon is the only drug of its kind available through prescription.
Doctor Michael Kilby is medical director of UAB's 1917 Clinic, a nonprofit health and research clinic focused solely on HIV and AIDS. Kilby says researchers are very excited about this drug.
More than 40 million people worldwide are infected with HIV. In Alabama, more than 9,300 people were living with HIV or AIDS in 2002. That's according to the Centers for Disease Control and Prevention.
Fuzeon works on patients whose bodies became resistant to traditional HIV treatments.